Twenty-Year Outcome and Association Between Early Treatment and Mortality and Disability in an Inception Cohort of Patients With Rheumatoid Arthritis

Results From the Norfolk Arthritis Register

James M. Gwinnutt,1 Deborah P. M. Symmons,2 Alexander J. MacGregor,3 Jacqueline R. Chipping,3 Tarnya Marshall,3 Mark Lunt,1 and Suzanne M. M. Verstappen1

Objective. To describe the outcome in patients with rheumatoid arthritis (RA) over 20 years from symptom onset, and to assess the association between early treatment (with disease-modifying antirheumatic drugs/steroids) and mortality and disability during follow-up.

Methods. Patients recruited to the Norfolk Arthritis Register (NOAR) between 1990 and 1994 who met the 2010 American College of Rheumatology/European League Against Rheumatism RA criteria at baseline were included in this analysis. Demographic and clinical variables were collected at baseline and at years 1–3, 5, 7, 10, 15, and 20. Disease activity (swollen joint count [SJC]/tender joint count [TJC]), disability (Health Assessment Questionnaire disability index [HAQ DI]), and mortality over 20 years were determined. Associations between treatment group (early treatment [ET], treatment ≤6 months after symptom onset; late treatment [LT], treatment >6 months after symptom onset; never treatment [NT], no treatment) and mortality and disability were assessed using weighted pooled logistic regression and weighted multilevel mixed-effects linear regression, respectively. Inverse weights were used to account for confounding by indication and censoring.

Results. This study included 602 patients with RA (median age 56 years [interquartile range 44–68 years]; 65.9% women). The median SJC and TJC were low during the follow-up period (1–3 swollen joints and 3–6 tender joints). The median HAQ DI score increased after year 1 but remained at low/moderate levels (median 1.25 after year 10). The risk of mortality was reduced in the ET and LT groups compared with that in the NT group. The ET group and the NT group had comparable HAQ DI scores during the follow-up period (for ET versus NT, \( \beta = 0.10 \) [95% CI 0.02, 0.17]).

Conclusion. The results of this study indicate the importance of early treatment with regard to the long-term outcomes in patients with RA.

Early rheumatoid arthritis (RA), a type of inflammatory polyarthritis, is a chronic disease primarily characterized by synovial joint inflammation (1). Both conditions (RA and inflammatory polyarthritis) may lead to progressive joint destruction and premature mortality (2–5). With appropriate therapy, however, this outcome can potentially be ameliorated (6–8), although there are relatively few studies investigating the long-term outcome in patients with RA (9–16). A previous study from the UK described the outcomes in 112 patients with RA who were recruited between 1964 and 1966 (prevalent cases) (mean age at symptom onset 45 years). Twenty years later, 35% of these
patients had died, and an additional 43% of the patients were classified as having moderate-to-high functional disability (17). The patients in this cohort were predominantly treated with steroids, gold, and chloroquine, which were standard treatments at that time.

Gathering new data on outcomes in the modern era is important, because over the last 2 decades there have been significant advances in available treatments and strategies for the management of RA (18,19). Methotrexate (MTX) has become the first-choice synthetic disease-modifying antirheumatic drug (DMARD) (18), and a number of biologic DMARDs have been introduced since 2000 (20). Previous research in patients with RA demonstrated an association between a reduced mortality risk and ever-exposure to MTX treatment over a mean of 6 years (6), reduced mortality risk and exposure to tumor necrosis factor inhibitor (TNFi) treatment over a mean of 4.9 years (21), as well as improved functional disability with MTX and TNFi therapy (22–25).

The aforementioned advances in treatment strategy included a shift toward initiating synthetic DMARD therapy early in the disease course, with the aim of treating patients within a “window of opportunity” in order to achieve maximal beneficial outcome (26,27). We previously showed that in patients with early inflammatory arthritis who received early treatment with synthetic DMARDs or steroids (initiation <6 months after symptom onset), the odds of having a high score (≥1) on the Health Assessment Questionnaire disability index (HAQ DI) (28) at 5 years were comparable with the odds in patients who never required treatment, after adjustment for differences in disease severity between the treatment groups. Those in whom therapy was initiated later (≥6 months after symptom onset) had 2-fold increased odds of having high HAQ DI scores compared with those who were never treated (29). Furthermore, those treated early showed a decrease in HAQ DI scores from baseline to year 10, which approached significance, while those treated later had increased HAQ DI scores at year 10 compared with baseline, again after adjustment for differences in disease severity between groups (30). Other groups of investigators have also shown the negative consequences of delayed assessment in terms of remission rates and joint destruction (31). However, the benefits of early treatment have yet to be demonstrated to extend past 10 years. It is also possible that the underlying natural history of RA may have changed over time (32).

In the current study, we investigated the outcome in patients with early RA over the course of 20 years, including mortality, disease activity, and physical function. We also examined the relationship between early synthetic DMARD or steroid therapy and mortality risk and physical function over 20 years.

**PATIENTS AND METHODS**

A total of 1,098 patients with inflammatory polyarthritis were recruited by the Norfolk Arthritis Register (NOAR) between 1990 and 1994. Detailed information about NOAR is presented elsewhere (33). Briefly, NOAR aimed to recruit and follow up prospectively all incident cases of inflammatory polyarthritis in the former Norwich Health Authority region, Norfolk, UK. These patients with inflammatory polyarthritis were referred by primary care physicians (a large majority of the UK population [99%] is registered with a primary care practice) or consultant rheumatologists. The inclusion criteria for this analysis were as follows: ≥16 years of age and ≥2 swollen joints for ≥4 weeks. Patients were excluded if they were recruited more than 2 years following symptom onset (76 patients were excluded). For this analysis, only patients who met the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) 2010 criteria for RA were included (34). The criteria were applied retrospectively to the baseline characteristics of the patients who were included (n = 614). Patients gave written consent, and the study was approved by the Norfolk and Norwich University Hospital Local Research Ethics Committee.

**Assessments.** Patients were assessed at baseline and at 1, 2, 3, 5, 7, 10, 15, and 20 years after registration. Patients were assessed beyond year 5 only if they had documented swollen joints on ≥2 occasions or had received DMARDs or oral corticosteroids by the fifth-year assessment (8 patients were excluded). Date of birth and sex were recorded at baseline. At each assessment, research nurses administered a standardized questionnaire (including smoking status [never/former/current]). The start and stop dates of treatment with all DMARDs and steroids were collected from patients at each follow-up visit. Patients who were receiving synthetic DMARDs or steroids before symptom onset (n = 12) were excluded from the analysis. Patients were classified into 1 of 3 treatment groups, with treatment being synthetic DMARDs and steroids: the early treatment (ET) group, in which patients received treatment ≤6 months after symptom onset; the late treatment (LT) group, in which patients received treatment >6 months after onset; and the never treatment (NT) group, in which patients never received treatment.

Comorbidities were self-reported at and after baseline and were coded based on the relevant chapters of the International Classification of Diseases, Ninth Edition and Tenth Edition (see Supplementary File 1, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40090/abstract). Once a patient reported a comorbidity, he or she was coded as having that comorbidity throughout the remainder of the follow-up period. Research nurses performed swollen joint counts (SJC) and tender joint counts (TJC) in 51 joints, from which 28-join counts were derived (except at follow-up visits 5 and 7). Blood samples were obtained at baseline. Serum was stored frozen, for determination of C-reactive protein (CRP; mg/liter), rheumatoid factor (RF; latex agglutination test, positive cutoff 40 units/ml), and anti-cyclic citrullinated peptide 2 (anti-CCP-2) antibodies (tested using a Diastat Anti-CCP kit, cutoff 5 units/ml [Axis-Shield]). Blood samples were then obtained every 5 years; in these samples, only the CRP level was determined. Disease activity was measured with the Disease Activity Score, using
3 variables: the number of swollen joints, the number of tender joints, and the CRP level (35), when CRP data were available.

Outcomes. Disease activity was analyzed based on the SJC in 51 joints and the TJC in 51 joints, as described above. All patients were flagged with the Office for National Statistics (ONS), the holders of the UK death register, which provided copies of death certificates including date of death and the underlying cause of death. The ONS also provided age- and sex-specific mortality rates by calendar year for the Norfolk population (1990–2013). Patients were censored at their 20th anniversary assessment or 20 years after symptom onset (if they did not attend the 20th assessment), with the exception of patients who left the country, who were censored on their departure date (7 patients with RA). At each assessment, patients completed the British Modification of the HAQ disability index (36), a validated self-report measure of functional disability that yields a score from 0 (no disability) to 3 (maximum disability).

Statistical analysis. Descriptive statistics were used to describe baseline demographic and clinical variables. Baseline scores were compared between treatment groups using the Kruskal-Wallis or chi-square test, depending on the type and distribution of data.

The standardized mortality ratio (SMR) was calculated for the cohort by comparing the observed numbers of deaths with the expected number of deaths for the local population based on age- and sex-specific mortality rates. Patients were included in this analysis until death, 20 years after symptom onset, or the end of 2013, whichever came first. The association between baseline variables, including age, sex, SJC in 51 joints, TJC in 51 joints, HAQ DI, CRP, RF, and anti–CCP-2, and mortality was assessed using a multivariate Cox proportional hazards model. To assess the association between treatment group and mortality, initially a Cox proportional hazards model, adjusted for age and sex, was used, and Kaplan-Meier survival curves were plotted. The SMR for each treatment group was also calculated. To account for confounding by indication, a weighted multivariate pooled logistic regression model was used (37,38), which produces odds ratios (ORs) that are equivalent to hazard ratios. Covariates included baseline measures (sex, smoking status, RF, anti–CCP-2, HAQ DI, 51-joint SJC, 51-joint TJC, and CRP), and data for time-varying measures where collected (HAQ DI, 51-joint SJC, 51-joint TJC, CRP, and comorbidities).

The median 51-joint SJC, 51-joint TJC, and HAQ DI scores and the numbers and proportions of patients receiving synthetic DMARDs were determined for each time point. The relationship between treatment group and disability over 20 years was assessed using a multilevel mixed-effects linear regression model, which is a longitudinal regression model that allows time-varying weights. Initially, only age and sex were controlled for using an unweighted model. To account for confounding by indication and censoring, a weighted multivariate model was then used, with the same covariates as those used for the pooled logistic regression described above (except time-varying HAQ DI scores).

To control for confounding by indication and censoring, inverse probability weights, which account for cumulative treatment exposure as well as censoring, were used to weight the covariates in the regression models (see Supplementary File 2, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40090/abstract), using methods adapted from those described by Fewell et al (37).

Multiple imputation, using iterative chained equations (5 imputed data sets were created) conditioned on baseline, lagged, and current assessment variables, was used to account for missing data on the assessments that patients attended. All regression analyses were also performed in the total population of patients with inflammatory polyarthritis (n = 1,000). Analysis was performed using Stata statistical software version 13.1 (StataCorp; 2013).

RESULTS

A total of 602 patients with RA were recruited between 1990 and 1994 and met all inclusion/exclusion criteria (median symptom duration 5.4 months, interquartile range [IQR] 2.9–9.9). The median age at symptom onset was 56 years (IQR 44–68 years), and 397 patients (65.9%) were women. The baseline characteristics of the patients are shown in Table 1.

In total, 160 patients (26.6%) received treatment within 6 months of symptom onset. Among these patients, 94 (58.8%) were prescribed sulfasalazine (SSZ), 45 (28.1%) were prescribed steroids, 8 (5.0%) were prescribed MTX, and 13 (8.1%) were prescribed other DMARDs. Among the remaining 442 patients, 88 (19.9%) received their first treatment within 6–12 months, 77 (17.4%) received treatment at 1–2 years, 84 (19.0%) received treatment ≥2 years after symptom onset, and 193 (43.7%) never received treatment while attending follow-up. Male patients were more likely to receive early treatment (n = 75 [46.9%]) compared with late treatment (n = 69 [27.7%]), and patients who received early treatment had a shorter disease duration at presentation (median 2.7 months) compared with those who received late treatment (median 7.4 months). Patients who received early treatment had worse clinical characteristics for all baseline variables compared with those who received late treatment or no treatment, except for TJC and autoantibody status (Table 1). Similar results were seen when all patients with inflammatory polyarthritis were included (for details, see Supplementary File 3, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40090/abstract).

A total of 207 patients (34.4%) were available for the 20-year assessment. During the follow-up period, 205 patients (34.1%) left the cohort due to death, 135 (22.4%) declined further follow-up visits, 8 (1.3%) became ineligible by year 5, and 47 (7.8%) were lost to follow-up (for details, see Supplementary File 4, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40090/abstract).

Because all patients were flagged with the ONS, mortality data were complete for the whole cohort up to the 20th anniversary assessment (even if follow-up ceased), except those who left the country. During 9,774 person-
years of follow-up (mean 14.8 years), 265 patients (44.0%) died. The age- and sex-standardized SMR for the cohort of patients with RA was increased compared with that for the general population in the Norfolk area (SMR 1.25 [95% CI 1.11, 1.42]). In a multivariate Cox regression analysis, older age at symptom onset (hazard ratio [HR] 1.10 per increased year of age at onset [95% CI 1.08, 1.11]) and male sex (HR 1.47 [95% CI 1.13, 1.92]) were associated with increased risk of death during that time period. Being a current smoker at baseline was independently associated with an increased risk of death compared with never smokers (HR 1.65 [95% CI 1.17, 2.33]) and former smokers (HR 1.82 [95% CI 1.34, 2.45]).

In total, 88 (55.0%) of the patients who received early treatment died over the course of follow-up compared with 99 (39.8%) of the patients who received late treatment and 78 (40.4%) of those who received no treatment. The SMR was increased in the ET group (SMR 1.28 [95% CI 1.03, 1.59]) and the LT group (SMR 1.23 [95% CI 1.01, 1.51]), and there was a trend toward significance for the NT group (SMR 1.25 [95% CI 0.99, 1.57]) compared with the general population of Norfolk. Within the cohort, there was little difference in the risk of death between treatment groups, after adjustment for age and sex (ET versus NT, HR 1.09 [95% CI 0.80, 1.11]; LT versus NT, HR 0.99 [95% CI 0.73, 1.33]) (Figure 1). After weighting to account for

---

### Table 1. Baseline characteristics of the total cohort of RA patients and according to treatment group

| Characteristic          | Cohort (n = 602) | ET (n = 160) | LT (n = 249) | NT (n = 193) | P† |
|-------------------------|------------------|--------------|--------------|--------------|----|
| Age at onset, years     | 56 (44–68)       | 62 (49–71)   | 54 (44–65)   | 55 (42–67)   | 0.0006‡ |
| Female sex, no. (%)     | 397 (66)         | 85 (53.1)    | 180 (72.3)   | 132 (68.4)   | <0.001 |
| Symptom duration, months| 5.4 (2.9–9.9)    | 2.7 (2.4–5.9)| 7.4 (3.8–12.0)| 5.1 (2.7–9.5)| 0.0001‡ |
| SJC in 28 joints         | 9 (4–14)         | 10 (5–16)    | 9 (4–14)     | 8 (4–13)     | 0.0243‡ |
| SJC in 51 joints         | 11 (6–17)        | 13 (6.5–20)  | 11 (6–18)    | 10 (5–15)    | 0.0247‡ |
| TJC in 28 joints         | 9.5 (4–16)       | 10 (4–17)    | 8 (4–15)     | 10 (6–16)    | 0.1503‡ |
| TJC in 51 joints         | 14 (7–23)        | 13 (5–22.5)  | 13 (6–23)    | 15 (9–22)    | 0.2272‡ |
| CRP, mg/liter¶           | 8 (1–22)         | 13.5 (6.8–38)| 8 (2–19)     | 3 (0–11)     | 0.0010‡ |
| DAS28#                   | 4.6 (3.8–5.5)    | 5.1 (4.1–6.0)| 4.5 (3.8–5.5)| 4.4 (3.7–5.3)| 0.0011‡ |
| HAQ DI score**           | 1.00 (0.50–1.63) | 1.25 (0.63–1.88)| 1.00 (0.50–1.63)| 0.88 (0.25–1.50)| 0.0001‡ |
| Smoking history, no. (%) | 177 (29.4)       | 42 (26.3)    | 80 (32.1)    | 55 (28.5)    | 0.441‡ |
| Never smoker             | 255 (42.4)       | 76 (47.5)    | 95 (38.2)    | 84 (43.5)    |               |
| Former smoker            | 170 (28.2)       | 42 (26.3)    | 74 (29.7)    | 54 (28.0)    |               |
| Current smoker           | 221 (40.3)       | 71 (46.4)    | 112 (49.8)   | 38 (22.4)    | <0.001§ |
| RF status††              | 327 (59.7)       | 82 (53.6)    | 113 (50.2)   | 132 (77.7)   |               |
| Positive, no. (%)        | 202 (41.1)       | 73 (52.5)    | 106 (54.6)   | 23 (14.6)    | <0.001§ |
| Negative, no. (%)        | 289 (58.9)       | 66 (47.5)    | 88 (45.4)    | 135 (85.4)   |               |
| Anti-CCP status§§        | 109 (18.1)       | 75 (46.9)    | 34 (13.7)    | 0 (0.0)      | <0.001§ |
| Positive, no. (%)        | 110 (18.1)       | 75 (46.9)    | 34 (13.7)    | 0 (0.0)      |               |
| Negative, no. (%)        | 289 (58.9)       | 66 (47.5)    | 88 (45.4)    | 135 (85.4)   |               |
| Current synthetic        | 109 (18.1)       | 75 (46.9)    | 34 (13.7)    | 0 (0.0)      |               |
| DMARD treatment, no. (%) | 8.4 (4.0–19.1)   | 3.1 (2.0–5.0)| 15.6 (10.0–36.2)| –          | <0.0001‡ |

* Complete data (100%) were available for all variables in all treatment groups, except for C-reactive protein (CRP), Disease Activity Score in 28 joints (DAS28), Health Assessment Questionnaire disability index (HAQ DI), rheumatoid factor (RF), and anti-cyclic citrullinated peptide (anti-CCP). Except where indicated otherwise, values are the median (interquartile range). RA = rheumatoid arthritis; SJC = swollen joint count; TJC = tender joint count.

† Across treatment groups.
‡ By Kruskal-Wallis test.
§ By chi-square test.
¶ The percent complete data for CRP level was 84.2% in the total cohort, 88.8% in the early treatment (ET) group (treatment ≤6 months after symptom onset), 83.1% in the late-treatment (LT) group (treatment >6 months after symptom onset), and 81.9% in the never treatment (NT) group (patient never received disease-modifying antirheumatic drugs [DMARDs] or steroids during follow-up).
# The percent complete data was 99.9% in the total cohort, 98.8% in the ET group, 98.8% in the LT group, and 99.5% in the NT group.
** The percent complete data was 99.9% in the total cohort, 98.8% in the ET group, 98.8% in the LT group, and 99.5% in the NT group.
†† The percent complete data was 91.0% in the total cohort, 95.6% in the ET group, 90.3% in the LT group, and 88.1% in the NT group.
§§ The percent complete data was 81.6% in the total cohort, 86.9% in the ET group, 77.9% in the LT group, and 88.1% in the NT group.
confounding by indication, the association between time to
first treatment and mortality risk remained nonsignificant
for the ET group, although there was a trend toward re-
duced risk of mortality (ET versus NT, adjusted OR
[OR adj] 0.78 [95% CI 0.54, 1.11]; LT versus NT, OR adj 0.66
[95% CI 0.47, 0.92]). When all patients with inflammatory
polyarthritis were included (n = 1,000), the results were
similar (ET versus NT, OR adj 0.82 [95% CI 0.61, 1.11]; LT
versus NT, OR adj 0.78 [95% CI 0.59, 1.03]).

Table 2 shows the median disease activity and func-
tional disability scores over follow-up for the patients with
RA, stratified by treatment group. All patients were
included in the analysis up to the point of their last follow-
up visit. The median SJC and TJC decreased rapidly in
the first year after baseline (median 11 swollen joints and
14 tender joints at baseline) and remained low throughout
follow-up (median SJC range 1–3, and median TJC range
3–6). Median HAQ DI scores for the total RA cohort also
decreased initially but then increased from the year 2 assess-
ment onward, culminating in a median score higher than
the baseline score after year 7 (median HAQ DI score of
1.25 after year 10 [IQR 0.50–2.00]) (Figure 2). The propor-
tion of patients receiving synthetic DMARDs was higher
in the ET group compared with the LT group until assess-
ment 2, after which time the proportions were comparable
(55–65%) (Table 2). Only a small proportion of patients
received biologic DMARDs during the study (7.6%), and
these patients were evenly distributed between the ET
group and the LT group (19 [11.9%] of 160 patients in the

Figure 1. Survival curves for rheumatoid arthritis patients in the 3 treatment groups, after adjustment for age and sex.

DISCUSSION

This study has 2 important messages: the first con-
cerns the long-term outcome in patients with RA in the
ET group, and 27 [10.8%] of 249 patients in the LT
group). Similar trends were observed when all patients
with inflammatory polyarthritis were included, although
with lower median scores due to lower disease severity in
this group (see Supplementary File 3, available on the
Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.40090/abstract).

Swollen and tender joint counts were similar
between treatment groups over the follow-up period,
excluding the baseline assessment. However, functional
disability was consistently higher in patients who received
treatment compared with patients who did not (Table 2).

After controlling for age and sex, there was an associ-
ation between being prescribed treatment and increased
HAQ DI scores over follow-up (Table 3). When the model
was fully adjusted and inverse probability weights were
applied to account for confounding by indication, patients
in the ET group had HAQ DI scores during follow-up sim-
ilar to those in the NT group (for ET versus NT, β = 0.03
[95% CI −0.06, 0.12]), whereas those in the LT group had
significantly higher disability scores over follow-up (LT
versus NT, β = 0.10 [95% CI 0.02, 0.17]). Similar results
were observed when all patients with inflammatory polyar-
thritis were included in the analysis.

This study has 2 important messages: the first con-
cerns the long-term outcome in patients with RA in the
Table 2. SJC and TJC in 51 joints, HAQ DI scores, and proportion of the 602 RA patients receiving synthetic DMARDs over 20-year follow-up, stratified by treatment group*

| Follow-up year | 0  | 1  | 2  | 3  | 5  | 7  | 10 | 15 | 20 |
|----------------|----|----|----|----|----|----|----|----|----|
| **SJC in 51 joints** |    |    |    |    |    |    |    |    |    |
| Total cohort      | 11 (6–17) | 3 (1–9) | 2 (0–8) | 2 (0–7) | – | – | 2 (0–5) | 1 (0–4) | 1 (0–3) |
| ET              | 13 (6.5–20) | 4 (1–10) | 3 (0–8) | 2.5 (0–9) | – | – | 2 (0–6) | 1 (0–4) | 0.5 (0–2) |
| LT              | 11 (6–18) | 4 (1–11) | 3 (1–9) | 3 (0–9) | – | – | 2 (0–7) | 1 (0–5) | 1 (0–4) |
| NT              | 10 (5–15) | 2 (1–8) | 1 (0–6) | 2 (0–5) | – | – | 1 (0–3) | 0.5 (0–2) | 0 (0–2) |
| **TJC in 51 joints** |    |    |    |    |    |    |    |    |    |
| Total cohort      | 14 (7–23) | 6 (2–15) | 5 (1–15) | 5 (1–15) | – | – | 3 (0–12) | 4 (0–15) | 4 (0–12) |
| ET              | 13 (5–22.5) | 5 (1–15) | 4 (1–13) | 4.5 (0–14.5) | – | – | 2 (0–11) | 2 (0–12) | 2.5 (0–5) |
| LT              | 13 (6–23) | 7 (1–17) | 7 (2–18) | 5 (2–16.5) | – | – | 4 (1–15) | 6 (1–19.5) | 6 (1–16) |
| NT              | 15 (9–22) | 6 (2–14) | 4 (1–12) | 4 (1–10.5) | – | – | 3 (0–10) | 3.5 (1–12) | 4 (0–7) |
| **HAQ DI score** |    |    |    |    |    |    |    |    |    |
| Total cohort      | 1.00 (0.50–1.63) | 0.75 (0.25–1.50) | 0.75 (0.25–1.63) | 0.88 (0.25–1.63) | 1.00 (0.38–1.75) | 1.13 (0.50–1.88) | 1.25 (0.38–2.00) | 1.25 (0.50–2.00) | 1.38 (0.50–2.00) |
| ET              | 1.25 (0.63–1.88) | 0.75 (0.13–1.56) | 0.88 (0.25–1.75) | 0.88 (0.25–1.63) | 1.06 (0.38–1.88) | 1.13 (0.50–1.88) | 1.25 (0.38–2.13) | 1.25 (0.75–2.13) | 1.38 (0.81–2.00) |
| LT              | 1.00 (0.50–1.63) | 0.88 (0.38–1.63) | 1.00 (0.25–1.75) | 1.13 (0.25–1.75) | 1.13 (0.38–1.75) | 1.25 (0.50–1.88) | 1.50 (0.63–2.00) | 1.50 (0.69–2.13) | 1.50 (0.69–2.13) |
| NT              | 0.88 (0.25–1.50) | 0.50 (0.13–1.25) | 0.50 (0.13–1.13) | 0.63 (0.00–1.25) | 0.88 (0.25–1.50) | 0.88 (0.25–1.50) | 1.00 (0.25–1.75) | 0.88 (0.25–1.38) | 0.88 (0.25–1.75) |
| **Synthetic DMARD, no. (%)** |    |    |    |    |    |    |    |    |    |
| Total cohort      | 109 (18.1) | 204 (35.7) | 203 (38.5) | 207 (41.0) | 179 (38.3) | 160 (40.6) | 153 (40.9) | 127 (45.2) | 98 (47.3) |
| ET              | 75 (46.9) | 98 (62.4) | 93 (63.7) | 85 (59.4) | 69 (45.8) | 56 (53.9) | 55 (57.3) | 45 (60.0) | 31 (57.4) |
| LT              | 34 (13.7) | 106 (43.1) | 110 (46.4) | 122 (54.0) | 110 (52.1) | 104 (55.6) | 98 (54.8) | 82 (58.6) | 67 (62.0) |
| NT              | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |

* Except where indicated otherwise, values are the median (interquartile range). SJC = swollen joint count; TJC = tender joint count; HAQ DI = Health Assessment Questionnaire disability index; RA = rheumatoid arthritis; ET = early treatment (treatment ≤ 6 months after symptom onset); LT = late treatment (treatment > 6 months after symptom onset); NT = never treatment (patient never received disease-modifying antirheumatic drugs [DMARDs] or steroids during follow-up).
modern era treated according to best practice at the time of presentation, and the second pertains to the benefit of early treatment, which is still apparent into the second decade after symptom onset with respect to functional disability.

Median SJC and TJC decreased after baseline and remained low during the follow-up period. Median functional disability decreased initially but then increased over time to above baseline levels by year 7 and then continued to increase up to year 20. Kapetanovic et al followed 183 Swedish patients with early RA for 20 years and showed a similar HAQ DI trajectory, with mean HAQ DI scores increasing to >1.0 at year 10 and thereafter (13). This level of functional disability is higher than that reported in healthy individuals of a similar age. In a random sample of adults in central Finland, the mean HAQ DI scores for all groups of individuals younger than age 75 years were <0.5 (39). Similar results were observed in a random sample of individuals older than age 65 years in Augsburg and Aichach-Friedberg, Germany (only 22.5% of the cohort had an HAQ DI score of ≥0.5) (40).

Despite the increase in median HAQ DI scores over 20 years, these results are encouraging. An HAQ DI score of 1.38 represents low to moderate disability (41). In contrast, a study that recruited 112 patients with RA in Droitwich, UK from 1964 to 1966 and followed them for a similar time period showed much higher levels of disability at 20 years (17). It thus appears that long-term disability in RA patients is now less severe. Furthermore, although the proportion of patients who died was similar in the Droitwich and NOAR studies, patients in the NOAR cohort had an older mean age at symptom onset (56 years versus 45 years in the Droitwich cohort).

### Table 3. Association between treatment regimen and the HAQ DI score over 20 years*

| Model, treatment regimen | RA patients | Total cohort |
|--------------------------|-------------|-------------|
|                          | No. of patients | β (95% CI) | No. of patients | β (95% CI) |
| Adjusted for age and sex |             |             |               |            |
| NT                       | 193         | 0           | 442           | 0          |
| LT                       | 249         | 0.27 (0.15, 0.39) | 347           | 0.37 (0.28, 0.46) |
| ET                       | 160         | 0.25 (0.11, 0.38) | 211           | 0.36 (0.26, 0.47) |
| Fully adjusted†          |             |             |               |            |
| NT                       | 193         | 0           | 442           | 0          |
| LT                       | 249         | 0.10 (0.02, 0.17) | 347           | 0.11 (0.06, 0.17) |
| ET                       | 160         | 0.03 (~0.06, 0.12) | 211           | 0.04 (~0.03, 0.11) |

* RA = rheumatoid arthritis; ET = early treatment (treatment <6 months after symptom onset); LT = late treatment (treatment >6 months after symptom onset); NT = never treatment (patient never received disease-modifying antirheumatic drugs or steroids during follow-up).
† Adjusted for sex and baseline anti–citrullinated protein antibodies, rheumatoid factor, smoking status, Health Assessment Questionnaire disability index (HAQ DI), swollen joint count (SJC), tender joint count (TJC), and C-reactive protein (CRP) level, and for time-varying measures, including age, CRP level, SJC, TJC, and comorbidities, and weighted using inverse probability of treatment/censoring weights.
The second finding from this study relates to the benefits of early DMARD therapy. We previously showed that treatment within the first 6 months following symptom onset is associated with benefits in physical function at 5 and 10 years, after appropriate adjustment for differences in disease severity (29,30). In the current analysis, we observed that, after adjustment for confounding by indication (i.e., adjusting for demographic and disease factors that may have influenced the decision to start DMARD or steroid treatment at baseline or subsequently), patients who were treated early had levels of disability over the follow-up period that were similar to those in patients who did not receive treatment, while patients treated later had significantly higher levels of disability over 20 years. This supports the importance of the “window of opportunity” construct for treatment, showing that early treatment leads to improved outcomes even into the second decade following symptom onset. Increased functional disability over time could be attributable to worse joint damage (42,43), and it has been shown that patients who receive later treatment have higher radiologic scores at follow-up compared with those treated early (8,44,45).

The SMRs for the total population and for the 2 treatment groups were elevated. The SMR for those who were never treated was increased to a similar extent but failed to reach significance. There was a trend toward reduced mortality risk in the ET group and a significant reduction in mortality risk in the LT group compared with the NT group. Treatment with MTX has previously been shown to be associated with a reduced medium-term risk of mortality in RA patients (6), and we previously showed that having disease in remission at least once within the first 3 years of follow-up was associated with reduced mortality risk in patients with inflammatory polyarthritis compared with the risk in patients who never achieved remission within the first 3 years of follow-up (median of 7.9 years) (46). It is the nature of the SMR that it approaches 1.00 as the length of follow-up increases, because all patients will eventually die.

This analysis has a number of strengths. It is one of the largest inception cohorts of patients with RA and inflammatory polyarthritis with a 20-year follow-up period. By retrospectively applying the 2010 ACR/EULAR criteria for RA (34), we have been able to study the subgroup of patients classified as having RA according to the latest criteria and compare their results with those of patients in the whole NOAR cohort and other published RA cohorts. The use of inverse probability weights to a longitudinal regression model allows us to control for confounding by indication over time. This is the current state-of-the-art approach in terms of controlling for confounding by indication and differs from approaches used in our previous work (28,29).

The attrition rates in this cohort are to be expected over a 20-year follow-up period. The use of inverse probability of censoring weights minimizes attrition bias. Because SJCs and TJC5s were not determined at follow-up visits 5 and 7, these time points could not be included in the longitudinal analyses. However, because we assessed a majority of these patients at assessments 3 and 10, patient disability should be modeled sufficiently.

A surprisingly high proportion of patients (32.1%) never received DMARDs or steroids. This reflects the fact that patients were recruited from primary and secondary care settings and followed up regardless of disease severity. If the study had been entirely based on continuing follow-up in secondary care, then patients with mild disease would have been discharged and contributed no follow-up information. Our study shows that patients who never received DMARD treatment did well and served as a useful group with which to compare the groups of patients who were treated either early or late.

Finally, these patients were recruited more than 20 years ago, meaning that the standard treatment at that time does not reflect best treatment practices today. Although this is a limitation, treatment practices are constantly evolving. If we wish to understand the 20-year outcome in RA patients, the only method is to study patients who were exposed to the treatment strategies used 20 years ago. Nevertheless, these results are still important, because they show clear improvement in these patients compared with patients studied in the prior 20-year period and also show that early treatment with predominantly SSZ or steroids is associated with improved outcomes 20 years later. Thus, because MTX is considered a more effective treatment than SSZ, the benefits of early treatment with MTX may be even greater after 20 years.

In conclusion, this cohort of RA patients had relatively low median levels of disease activity from year 1 onward. In contrast, the median level of disability increased to above baseline levels after 7 years. This disability is still moderate. Thus, on average, patients experienced relatively good long-term outcomes, particularly compared with those observed in an earlier UK cohort recruited from 1964 to 1966 and followed up for 20 years. As might be expected, early therapy was given to patients with more severe disease. After adjustment for this confounding by indication over time, functional disability was greater in the LT group compared with the NT group over the course of follow-up, while the ET group had levels of disability similar to those in the NT group, indicating that the benefits of early treatment were sustained long term.
ACKNOWLEDGMENTS

We thank the patients involved in NOAR, as well as the clinical staff at Norfolk and Norwich Hospital, local primary care physicians, and the NOAR research nurses. We also thank the data management team at the University of Manchester.

AUTHOR CONTRIBUTIONS

All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published. Dr. Verstappen had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study conception and design. Gwinnutt, Symmons, MacGregor, Verstappen.

Acquisition of data. Chipping, Marshall.

Analysis and interpretation of data. Gwinnutt, Symmons, Lunt, Verstappen.

REFERENCES

1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010;376:1094–108.
2. Fuchs HA, Kaye JJ, Callahan LF, Nance EP, Pincus T. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 1989;16:585–91.
3. Van der Heijde DM. Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol 1995;34 Suppl 2:74–8.
4. Mitchell DM, Spitz PW, Young DY, Bloch DA, McShane DJ, Fries JF. Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum 1986;29:706–14.
5. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481–94.
6. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173–7.
7. Sharp JT, Strand V, Leung H, Hurley F, Loew-Friedrich I, on behalf of the Leflunomide Rheumatoid Arthritis Investigators Group. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 2000;43:495–505.
8. Bukhari MA, Wiles NJ, Lunt M, Harrison BJ, Scott DG, Symmons DP, et al. Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthritis Rheum 2003;48:46–53.
9. Goodson NJ, Symmons DP, Scott DG, Bunn D, Lunt M, Silman AJ. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care–based inception cohort. Arthritis Rheum 2005;52:2293–9.
10. Farragher TM, Lunt M, Bunn DK, Silman AJ, Symmons DP. Early functional disability predicts both all-cause and cardiovascular mortality in people with inflammatory polyarthritis: results from the Norfolk Arthritis Register. Ann Rheum Dis 2007;66:848–92.
11. Lindqvist E, Saxne T, Geborek P, Eberhardt K. Ten year outcome in a cohort of patients with early rheumatoid arthritis: health status, disease process, and damage. Ann Rheum Dis 2002;61:1055–9.
12. Courvoisier N, Dougdas M, Cantagrel A, Goupille P, Meyer O, Sibilia J, et al. Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective study. Arthritis Res Ther 2008;10:R106.
13. Kapetanovic MC, Lindqvist E, Nilsson JA, Geborek P, Saxne T, Eberhardt K. Development of functional impairment and disability in rheumatoid arthritis patients followed for 20 years: relation to disease activity, joint damage, and comorbidity. Arthritis Care Res (Hoboken) 2012;67:340–8.
14. Capell H, McCarey D, Madhok R, Hampson R. “5D” outcome in 52 patients with rheumatoid arthritis surviving 20 years after initial disease modifying antirheumatic drug therapy. J Rheumatol 2002;29:2099–105.
15. Rasker JJ, Cosy JA. The natural history of rheumatoid arthritis over 20 years: clinical symptoms, radiological signs, treatment, mortality and prognostic significance of early features. Clin Rheumatol 1987;6 Suppl 2:5–11.
16. Wolfe F, Rasker JJ, Boers M, Wells GA, Michaud K. Minimal disease activity, remission, and the long-term outcomes of rheumatoid arthritis. Arthritis Rheum 2007;57:935–42.
17. Scott DL, Symmons DP, Coulton BL, Popert AJ. Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet 1987;1:1108–11.
18. Pincus T, Yazici Y, Sokka T, Aletaha D, Smolen JS. Methotrexate as the “anchor drug” for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 2003;21:S179–85.
19. van Vollenhoven RF. Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol 2009;5:531–41.
20. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004;350:2167–79.
21. Jacobsson LT, Turesson C, Nilsson JA, Petersson IF, Lindqvist E, Saxne T, et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:670–5.
22. Lie E, Uhlig T, van der Heijde D, Rodevant E, Kalstad S, Kaufmann C, et al. Effectiveness of sulfasalazine and methotrexate in 1102 DMARD-naive patients with early RA. Rheumatology (Oxford) 2012;51:670–8.
23. Gaujoux-Viala C, Paternotte S, Combe B, Dougdos M. Evidence of the symptomatic and structural efficacy of methotrexate in daily practice as the first disease-modifying drug in rheumatoid arthritis despite its suboptimal use: results from the ESPOIR early synovitis cohort. Rheumatology (Oxford) 2012;51:1648–54.
24. Keystone EC, Kavanagh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, phase-2 controlled, 52-week trial. Arthritis Rheum 2004;50:1400–11.
25. Van der Heijde D, Klareскиog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Mels-Gomes J, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006;54:1063–74.
26. Quinn MA, Emery P. Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin Exp Rheumatol 2003;21:S154–7.
27. Cuth JI. Early rheumatoid arthritis: is there a window of opportunity? J Rheumatol Suppl 2007;80:1–7.
28. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137–45.
29. Wiles NJ, Lunt M, Barrett EM, Bukhari M, Silman AJ, Symmons DP, et al. Reduced disability at five years with early treatment of inflammatory polyarthritis: results from a large observational cohort, using propensity models to adjust for disease severity. Arthritis Rheum 2001;44:1033–42.
30. Farragher TM, Lunt M, Bu B, Bunn D, Symmons DP. Early treatment with, and time receiving, first disease-modifying anti-rheumatic drug predicts long-term function in patients with inflammatory polyarthritis. Ann Rheum Dis 2010;69:689–95.
31. Van der Linden MP, le Cessie S, Raza K, van der Woude D, Knevel R, Huizinga TW, et al. Long-term impact of delay in
assessment of patients with early arthritis. Arthritis Rheum 2010; 62:5537–46.
32. Diffin JG, Lunt M, Marshall T, Chipping JR, Symmons DP, Verstappen SM. Has the severity of rheumatoid arthritis at presentation diminished over time? J Rheumatol 2014;41:1590–9.
33. Symmons DP, Barrett EM, Bankhead CR, Scott DG, Silman AJ. The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register. Br J Rheumatol 1994;33:735–9.
34. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569–81.
35. Fransen J, Welsing P, de Keijzer R, van Riel P. Disease activity scores using C-reactive protein: CRP may replace ESR in the assessment of RA disease activity [abstract]. Ann Rheum Dis 2004;62:151.
36. Kirwan JR, Reeback JS. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol 1986;25:206–9.
37. Fewell Z, Hernán M, Wolfe F, Tilling K, Choi HK, Sterne J. Controlling for time-dependent confounding using marginal structural models. Stata J 2004;4:402–20.
38. Brunelli SM, Chertow GM, Ankers ED, Lowrie EG, Thadhani R. Shorter dialysis times are associated with higher mortality among incident hemodialysis patients. Kidney Int 2010;77:630–6.
39. Krishnan E, Sokka T, Hakkinen A, Hubert H, Hannonen P. Normative values for the Health Assessment Questionnaire disability index: benchmarking disability in the general population. Arthritis Rheum 2004;50:953–60.
40. Strobl R, Muller M, Emery P, Peters A, Grill E. Distribution and determinants of functioning and disability in aged adults: results from the German KORA-Age study. BMC Public Health 2013;13:137.
41. Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: dimensions and practical applications. Health Qual Life Outcomes 2003;1:20.
42. Scott DL, Pugner K, Kaarela K, Doyle DV, Woolf A, Holmes J, et al. The links between joint damage and disability in rheumatoid arthritis. Rheumatology (Oxford) 2000;39:122–32.
43. Smolen JS, Aletaha D, Grisar JC, Stamm TA, Sharp JT, Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials. Ann Rheum Dis 2010;69:1058–64.
44. Lukas C, Combe B, Ravaud P, Sibilia J, Landewe R, van der Heijde D. Favorable effect of very early disease-modifying anti-rheumatic drug treatment on radiographic progression in early inflammatory arthritis: data from the Etude et Suivi des Polyarthrites Indifférenciées Récentes (study and follow-up of early undifferentiated polyarthritis). Arthritis Rheum 2011;63:1804–11.
45. Finckh A, Liang MH, van Herckenrode CM, de Pablo P. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis. Arthritis Rheum 2006;55:864–72.
46. Scire CA, Lunt M, Marshall T, Symmons DP, Verstappen SM. Early remission is associated with improved survival in patients with inflammatory polyarthritis: results from the Norfolk Arthritis Register. Ann Rheum Dis 2014;73:1677–82.